HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Evaluation of protein-losing enteropathy in the cirrhotic patient by assessing the intestinal clearance of alpha 1 antitrypsin (author's transl)].

Abstract
The purpose of this study was to evaluate protein-losing enteropathy in cirrhotic patients by assaying the intestinal clearance of alpha 1 antitrypsin (C alpha 1), 28 patients were divided into 5 groups: group A = 4 controls, group B = 6 patients with peptic ulcer, group C = 5 cirrhotic patients without esophageal varices (EV), group D = 6 cirrhotic patients with EV but without ascites, group E = 7 cirrhotic patients with EV and ascites. A significant increase in C alpha 1 was found only in groups D and E. The C 1 level was equal to the mean level found in controls multiplied by 2.5 and added to 2 standard deviations. Increases in C alpha 1 levels were not statistically significant when ascites or gastrointestinal involvement were present. C alpha 1 was significantly correlated to the size of EV (p greater than 0.05) and with the Child ratio (p greater than 0.01). No significant correlation was found between C alpha 1 and serum albumin or prothrombin.
AuthorsJ F Bretagne, P Lemee, E Esvant, J Gastard
JournalLa semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris (Sem Hop) Vol. 58 Issue 10 Pg. 575-7 (Mar 11 1982) France
Vernacular TitleEvaluation de l'entéropathie exsudative chez le patient cirrhotique par la mesure de la clairance intestinal de l'alpha 1-antitrypsine.
PMID6278598 (Publication Type: Journal Article)
Chemical References
  • alpha 1-Antitrypsin
Topics
  • Humans
  • Intestinal Mucosa (metabolism)
  • Liver Cirrhosis, Alcoholic (complications, metabolism)
  • Protein-Losing Enteropathies (diagnosis, etiology, metabolism)
  • alpha 1-Antitrypsin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: